Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BeOne Medicines Ltd. Director's Dealing 2025

Feb 6, 2025

30073_dirs_2025-02-06_ee7037cc-3693-4965-b6fa-d870b96b6a1c.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BeiGene, Ltd. (BGNE)
CIK: 0001651308
Period of Report: 2025-02-04

Reporting Person: Wang Xiaodong (Director, Chair, Scientific Advisory Brd)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2025-02-04 American Depositary Shares M 41760 $6.50 Acquired 41760 Direct
2025-02-04 American Depositary Shares S 9099 $222.998 Disposed 32661 Direct
2025-02-04 American Depositary Shares S 1519 $224.1816 Disposed 31142 Direct
2025-02-04 American Depositary Shares S 2161 $225.2686 Disposed 28981 Direct
2025-02-04 American Depositary Shares S 17805 $226.3504 Disposed 11176 Direct
2025-02-04 American Depositary Shares S 9776 $226.9979 Disposed 1400 Direct
2025-02-04 American Depositary Shares S 1400 $228.0421 Disposed 0 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2025-02-04 Share Option (Right to Buy) $0.50 M 542880 Disposed 2025-07-19 Ordinary Shares (542880) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Ordinary Shares 5240882 Direct
Ordinary Shares 1025063 Indirect
Ordinary Shares 4058998 Indirect
Ordinary Shares 50 Indirect

Footnotes

F1: These securities are held by a family trust, the beneficiaries of which are the Reporting Person's family members, for which the Reporting Person disclaims beneficial ownership.

F2: These securities are held by Wang Investment LLC, of which 99% of the limited liability company interest is owned by two grantor retained annuity trusts, of which the Reporting Person's wife is a trustee, for which the Reporting Person disclaims beneficial ownership.

F3: These securities are held by the spouse of the Reporting Person.

F4: Each American Depositary Share represents 13 Ordinary Shares.

F5: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on August 12, 2024.

F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $222.70 to $223.69, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $223.70 to $224.68, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $224.73 to $225.72, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $225.74 to $226.73, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $226.74 to $227.60, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $228.04 to $228.055, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

F12: These securities vest over a five-year period as follows: 20% on July 19, 2016, and the remaining in 48 successive equal monthly installments, subject to continued service. The expiration date of the share option is July 19, 2025.